Menu

Filtros : "ESCLEROSE MÚLTIPLA" "FCFRP" Removido: "Canadá" Limpar

Filtros

Refine with date range

  • 1

1 - 2 (2 records)

  • Artigo de periodico-carta/editorial

    Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II (2022)

    Malmegrim, Kelen Cristina Ribeiro ; Toubert, A.; Farge, D.; Rodrigues, Maria Carolina de Oliveira

    Source: Frontiers in Immunology. Unidades: FCFRP, FMRP

    Subjects: DOENÇAS AUTOIMUNES, TRANSPLANTE AUTÓLOGO, CÉLULAS-TRONCO, ESCLEROSE MÚLTIPLA

    Versão PublicadaAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      MALMEGRIM, Kelen Cristina Ribeiro et al. Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II. Frontiers in Immunology. Lausanne: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.3389/fimmu.2022.1038338. Acesso em: 17 out. 2024. , 2022

    • APA

      Malmegrim, K. C. R., Toubert, A., Farge, D., & Rodrigues, M. C. de O. (2022). Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II. Frontiers in Immunology. Lausanne: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.3389/fimmu.2022.1038338

    • NLM

      Malmegrim KCR, Toubert A, Farge D, Rodrigues MC de O. Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II [Internet]. Frontiers in Immunology. 2022 ; 13 1-3.[citado 2024 out. 17 ] Available from: https://doi.org/10.3389/fimmu.2022.1038338

    • Vancouver

      Malmegrim KCR, Toubert A, Farge D, Rodrigues MC de O. Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II [Internet]. Frontiers in Immunology. 2022 ; 13 1-3.[citado 2024 out. 17 ] Available from: https://doi.org/10.3389/fimmu.2022.1038338

  • Artigo de periodico

    Enantioselectivity in the metabolism of cyclophosphamide in patients with multiple or systemic sclerosis (2017)

    Castro, Francine Attié de; Simões, Belinda Pinto; Coelho, Eduardo Barbosa; Lanchote, Vera Lúcia

    Source: The Journal of Clinical Pharmacology. Unidades: FMRP, FCFRP

    Subjects: CITOCINAS, FÁRMACOS IMUNOSSUPRESSORES, ESCLEROSE MÚLTIPLA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      CASTRO, Francine Attié de et al. Enantioselectivity in the metabolism of cyclophosphamide in patients with multiple or systemic sclerosis. The Journal of Clinical Pharmacology, v. 57, n. 6, p. 784-795, 2017Tradução . . Disponível em: https://doi.org/10.1002/jcph.863. Acesso em: 17 out. 2024.

    • APA

      Castro, F. A. de, Simões, B. P., Coelho, E. B., & Lanchote, V. L. (2017). Enantioselectivity in the metabolism of cyclophosphamide in patients with multiple or systemic sclerosis. The Journal of Clinical Pharmacology, 57( 6), 784-795. doi:10.1002/jcph.863

    • NLM

      Castro FA de, Simões BP, Coelho EB, Lanchote VL. Enantioselectivity in the metabolism of cyclophosphamide in patients with multiple or systemic sclerosis [Internet]. The Journal of Clinical Pharmacology. 2017 ; 57( 6): 784-795.[citado 2024 out. 17 ] Available from: https://doi.org/10.1002/jcph.863

    • Vancouver

      Castro FA de, Simões BP, Coelho EB, Lanchote VL. Enantioselectivity in the metabolism of cyclophosphamide in patients with multiple or systemic sclerosis [Internet]. The Journal of Clinical Pharmacology. 2017 ; 57( 6): 784-795.[citado 2024 out. 17 ] Available from: https://doi.org/10.1002/jcph.863
  • 1

1 - 2 (2 records)

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024